| BioLamina–Lauxera: investment, 202309 investment €17m by Lauxera Growth I fund |
2023-09-12 |
| IO Biotech–SEVERAL: investment, 202308 private placement $75m with existing + new investors |
2023-08-07 |
| Crescendo Biologics–Andera Partners: investment, 202307 financing round totalling $32m incl existing investor Andera Partners |
2023-07-24 |
| Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors |
2023-07-24 |
| Crescendo Biologics–Sofinnova: investment, 202307 financing round totalling $32m incl existing investor Sofinnova Partners |
2023-07-24 |
| Abionyx–NewCap: public relations, 202307 service existent by NewCap |
2023-07-13 |
| EG 427–SEVERAL: investment, 202307 financing round Series A €5m final closing bringing total Series A to €18m |
2023-07-13 |
| Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital |
2023-07-12 |
| Tenpoint Therapeutics–Sofinnova: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor Sofinnova Partners |
2023-07-12 |
| Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries |
2023-07-11 |
| Flash Therapeutics–NewCap: public relations, 202307 service existent by NewCap |
2023-07-06 |
| Exeliom Biosciences–Auriga Partners: investment, 202306 financing round Series A extension totalling €8m incl existing + co-investor Auriga Partners |
2023-06-30 |
| Exeliom Biosciences–Biocodex: investment, 202306 financing round Series A extension totalling €8m incl existing + co-investor Biocodex |
2023-06-30 |
| Exeliom Biosciences–Capital Grand Est: investment, 202306 financing round Series A extension totalling €8m incl existing + co-investor Capital GE |
2023-06-30 |
| Exeliom Biosciences–Crescent Enterprises: investment, 202306 financing round Series A extension totalling €8m incl new + lead investor CE-Ventures |
2023-06-30 |
| Exeliom Biosciences–SEVERAL: investment, 202306 financing round Series A extension €8m + final closing at total of €18m |
2023-06-30 |
| Exeliom Biosciences–UI Investissement: investment, 202306 financing round Series A extension totalling €8m incl existing + co-investor UII |
2023-06-30 |
| Gleamer–Alize RP: public relations, 202306 service existent press contact Alize RP |
2023-06-28 |
| Gleamer–Crista Galli Ventures: investment, 202306 financing round Series B totalling €27m incl existing + co-investor Crista Galli Ventures |
2023-06-28 |
| Gleamer–Elaia Partners: investment, 202306 financing round Series B totalling €27m incl existing + co-investor Elaia |
2023-06-28 |
| Gleamer–France (govt): investment, 202306 financing round Series B totalling €27m incl existing + co-investor Bpifrance via Digital Venture + F3A |
2023-06-28 |
| Gleamer–Heal Capital: investment, 202306 financing round Series B totalling €27m incl new + co-lead investor Heal Capital |
2023-06-28 |
| Gleamer–MACSF: investment, 202306 financing round Series B totalling €27m incl existing + co-investor MACSF |
2023-06-28 |
| Gleamer–PERSON: investment, 202306 financing round Series B totalling €27m incl several European radiologists |
2023-06-28 |
| Gleamer–SEVERAL: investment, 202306 financing round Series B €27m led by Supernova Invest + co-led by Heal Capital |
2023-06-28 |
| Gleamer–Siparex: investment, 202306 financing round Series B totalling €27m incl existing + co-investor XAnge |
2023-06-28 |
| Gleamer–Supernova Invest: investment, 202306 financing round Series B totalling €27m incl new + lead investor Supernova Invest |
2023-06-28 |
| Gleamer–UI Investissement: investment, 202306 financing round Series B totalling €27m incl existing + co-investor UI Investissement |
2023-06-28 |
| Astraveus–AdBio Partners: investment, 202306 seed financing round totalling €16.5m incl lead investor AdBio Partners |
2023-06-27 |
| Astraveus–France (govt): investment, 202306 seed financing round totalling €16.5m incl co-investor Bpifrance Large Venture |
2023-06-27 |
| Astraveus–JnJ: investment, 202306 seed financing round totalling €16.5m incl co-investor JJDC Inc |
2023-06-27 |
| Astraveus–Merck (DE): investment, 202306 seed financing round totalling €16.5m incl co-investor M Ventures |
2023-06-27 |
| Astraveus–Optimum Strategic Communications: public relations, 202306 service existent by Optimum |
2023-06-27 |
| Astraveus–SEVERAL: investment, 202306 seed financing round €16.5m led by AdBio Partners |
2023-06-27 |
| Carthera–EU (govt): investment, 202306 financing round Series B totalling €37.5m incl co-investor EIC Fund |
2023-06-27 |
| Carthera–OTHER: investment, 202306 financing round Series B totalling €37.5m incl prominent undisclosed lead investor |
2023-06-27 |
| Carthera–Panakès Partners: investment, 202306 financing round Series B totalling €37.5m incl existing + co-investor Panakès Partners |
2023-06-27 |
| Carthera–Relyens: investment, 202306 financing round Series B totalling €37.5m incl existing + co-investor Relyens Innovation Santé (Turenne Santé) |
2023-06-27 |
| Carthera–SEVERAL: investment, 202306 financing round Series B €37.5m led by undisclosed investor |
2023-06-27 |
| Carthera–Supernova Invest: investment, 202306 financing round Series B totalling €37.5m incl existing + co-investor Supernova 2 Fund |
2023-06-27 |
| Carbios–SEVERAL: investment, 202306–202307 capital increase €122.4m+€18.4m with 4.8m+725k new shares at €25,32/share |
2023-06-22 |
| Sanofi–SandboxAQ: AI-based drug discovery, 202306 collab existent disclosed of Sanofi with AQBioSim |
2023-06-22 |
| Nuage Therapeutics–Asabys Partners: investment, 202306 seed financing round totalling €12m incl co-lead investor Asabys Partners |
2023-06-20 |
| Nuage Therapeutics–SEVERAL: investment, 202306 seed financing round €12m led by Sofinnova Partners + Asabys with Innvierte + BStartup |
2023-06-20 |
| Nuage Therapeutics–Sofinnova: investment, 202306 seed financing round totalling €12m incl co-lead investor Sofinnova Partners |
2023-06-20 |
| AAVantgarde Bio–SEVERAL: investment, 202306 financing round Series A €61m led by Atlas Venture + Forbion |
2023-06-06 |
| Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform |
2023-06-05 |
| 4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
| Dualyx–Andera Partners: investment, 202305 financing round Series A totalling €40m incl new + co-lead investor Andera Partners |
2023-05-15 |
| Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners |
2023-05-15 |
| DiogenX–AdBio Partners: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor AdBio Partners |
2023-05-10 |
| DiogenX–Boehringer: investment, 202305 financing round Series A totalling €27.5m incl existing + co-lead investor Boehringer Ingelheim Venture Fund |
2023-05-10 |
| DiogenX–Juvenile Diabetes Research Foundation: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor JDRF T1D Fund |
2023-05-10 |
| DiogenX–Lilly: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Eli Lilly |
2023-05-10 |
| DiogenX–Omnes Capital: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Omnes |
2023-05-10 |
| DiogenX–Roche: investment, 202305 financing round Series A totalling €27.5m incl new + co-lead investor Roche Venture Fund |
2023-05-10 |
| DiogenX–SEVERAL: investment, 202305 financing round Series A €27.5m led by BIVF + Roche Venture Fund |
2023-05-10 |
| Evommune–SEVERAL: investment, 202304 financing round Series B $50m co-led by Arix Bioscience + EQT Life Sciences + SymBiosis |
2023-04-26 |
| Ariceum Therapeutics–Andera Partners: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Andera |
2023-04-18 |
| Ariceum Therapeutics–SEVERAL: investment, 202304 financing round Series A extension €22.75m bringing total Series A to €47.75m |
2023-04-18 |
| Alia Therapeutics–Indaco Venture: investment, 202304 seed financing round extension totalling €4.4m incl co-investor Indaco Bio |
2023-04-17 |
| Alia Therapeutics–SEVERAL: investment, 202304 seed financing round extension €4.4m led by Sofinnova Telethon Fund |
2023-04-17 |
| Alia Therapeutics–Sofinnova: investment, 202304 seed financing round extension totalling €4.4m incl existing + lead investor Sofinnova Telethon Fund |
2023-04-17 |
| Alentis Therapeutics–France (govt): investment, 202304 financing round Series C totalling $105m incl existing + co-investor InnoBio 2 Fund |
2023-04-13 |
| Alentis Therapeutics–Jeito Capital: investment, 202304 financing round Series C totalling $105m incl existing + lead investor Jeito Capital |
2023-04-13 |
| Alentis Therapeutics–SEVERAL: investment, 202304 financing round Series C $105m led by Jeito Capital with Novo Holdings + RA Capital |
2023-04-13 |
| Calida Therapeutics–AdBio Partners: investment, 202304c seed financing €2m from AdBio Partners |
2023-04-06 |
| Polyplus-transfection–Sartorius: investment, 202303– acquisition €2.4b of Polyplus by SSB from Archimed + Warburg Pincus et al |
2023-03-31 |
| Galapagos–Novalix: drug discovery services, 202303– collab 5 years in connection with acquisition of Galapagos Romainville by Novalix |
2023-03-30 |
| Galapagos–Novalix: investment, 202303– acquisition of Romainvaille operations of Galapagos by Novalix |
2023-03-30 |
| Deepc–SEVERAL: investment, 202303 financing round Series A €12m led by Sofinnova Partners |
2023-03-28 |
| Deepc–Sofinnova: investment, 202303 financing round Series A totalling €12m incl new + lead investor Sofinnova Partners |
2023-03-28 |
| Kiro (FR)–SEVERAL: investment, 202303 financing round Series A €13.8m led by Sofinnova Partners |
2023-03-28 |
| Kiro (FR)–Sofinnova: investment, 202303 financing round Series A totalling €13.8m incl new + lead investor Sofinnova Partners |
2023-03-28 |
| Lys Therapeutics–Michael J Fox Foundation: grant, 202303– funding >$600k for preclinical research of glunozumab for Parkinson’s disease |
2023-03-15 |
| Mediar Therapeutics–SEVERAL: investment, 202303c financing round Series A $85m co-led by NVF + Sofinnova Partners |
2023-03-15 |
| Mediar Therapeutics–Sofinnova: investment, 202303c financing round Series A totalling $85m incl co-lead investor Sofinnova Partners |
2023-03-15 |
| AlgoTherapeutix–France (govt): investment, 202303 financing round Series B totalling €20m incl existing + co-investor Innobio 2 Fund of Bpifrance |
2023-03-14 |
| AlgoTherapeutix–Omnes Capital: investment, 202303 financing round Series B totalling €20m incl existing + co-investor Omnes Capital |
2023-03-14 |
| AlgoTherapeutix–OTHER: investment, 202303 financing round Series B totalling €20m incl existing + new business angel investors |
2023-03-14 |
| AlgoTherapeutix–Relyens: investment, 202303 financing round Series B totalling €20m incl new + lead investor Relyens Innovation Santé |
2023-03-14 |
| AlgoTherapeutix–SEVERAL: investment, 202303 financing round Series B €20m led by Relyens Innovation Santé advised by Turenne Capital |
2023-03-14 |
| AlgoTherapeutix–UI Investissement: investment, 202303 financing round Series B totalling €20m incl new + co-investor FCPI Majycc Innovation Santé |
2023-03-14 |
| Provention Bio–Sanofi: investment, 202303– acquisition $2.9b cash temder offer for Provention Bio by Sanofi at $25/share ANNOUNCED |
2023-03-13 |
| Chiesi–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Galapagos–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Iktos–Debiopharm: investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor Debiopharm Innovation Fund |
2023-03-09 |
| Iktos–Merck (DE): investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor M Ventures |
2023-03-09 |
| Iktos–Omnes Capital: investment, 202303 financing round Series A totalling €15.5m incl co-investor Omnes Capital |
2023-03-09 |
| Iktos–SEVERAL: investment, 202303 financing round Series A €15.5m co-led by M Ventures + Debiopharm Innovation Fund |
2023-03-09 |
| Ono Pharmaceutical–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Pfizer–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Servier–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Teijin–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| UCB–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Noema Pharma–SEVERAL: investment, 202303 financing round Series B CHF103m ($12m) co-led by Forbion + Jeito Capital |
2023-03-07 |
| Avilar Therapeutics–Sanofi: investment, 202302 seed financing round extension totalling $15m incl new investor Sanofi Ventures |
2023-02-16 |
| Avilar Therapeutics–SEVERAL: investment, 202302 seed financing round extension $15m bringing total seed round to $75m |
2023-02-16 |
| InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital |
2023-01-17 |
| InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership |
2023-01-17 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
